Liquid Biopsy Market Outlook 2024: Top Companies, Trends and Growth Factors Details for Business Development

2019 Research Report on Global Liquid Biopsy Market is a professional and comprehensive report on the Liquid Biopsy industry.

#Download Free PDF Sample Brochure of report Global Liquid Biopsy Market 2019 across with 204 Pages and in-depth TOC Analysis @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=631133

Key Players: QIAGEN N.V. (Netherlands), Roche Diagnostics (US),Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDxHealth SA (US).

"Global liquid biopsy market projected to grow at a CAGR of 23.4%"

The global liquid biopsy market is estimated to grow at a CAGR of 23.4% from 2017 to 2022, to reach USD 2,047.9 million by 2022. Increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear Regulatory and reimbursement scenario is one of the major challenges faced by the market.

"Extracellular vesicles to register the highest CAGR during the forecast period"

Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers. The extracellular vesicles segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring.

"The non-cancer application segment is projected to grow at the highest CAGR during the forecast period"

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.

"Asia Pacific to witness the highest growth during the forecast period (2017-2022)"

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.

Place a Direct Purchase Order and Get Flat 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=631133

In the end, the Global Liquid Biopsy Market report's conclusion part notes the estimation of the industry veterans.

Connect Us for more information at sales@reportsandreports.com or Call Us + 1 888 391 5441.

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.